Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

NCT05859477 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Gastric Cancer
PD-L1 Gene Amplification
FGFR2 Amplification

Interventions

DRUG: Nivolumab
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Kidney Cancer Research Bureau